Mode of Action for Santhera's Catena and its Relevance for Mitochondrial Disorders Revealed
"From previous studies it was clear that idebenone can transfer electrons onto complex III of the mitochondrial electron transport chain. This new work now closes the gap in our understanding how exactly this transfer is accomplished", summarized Thomas Meier, Santhera's Chief Scientific Officer. "Biochemical and cellular experiments now show that the cytosolic enzyme NQO1 uses idebenone as a substrate, which in turn can transport electrons into the mitochondria and onto complex III. This shuttling of electrons effectively by-passes the deficient complex I and increases the levels of ATP."
Idebenone, a short-chain benzoquinone, holds therapeutic potential for several mitochondrial and neuromuscular disorders. Researchers at Santhera now found that idebenone upon reduction by the cytosolic enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) generates a cytosolic-mitochondrial electron shuttle that can effectively bypass complex I of the mitochondrial electron transport chain and increase cellular energy levels. Interestingly, this mechanism is not shared with long-chain quinones, such as Coenzyme Q10, which is a poor substrate for NQO1. This mode of action for idebenone is particularly relevant for disorders characterized by deficiencies of the mitochondrial complex I, such as Leber's Hereditary Optic Neuropathy (LHON), Mitochondrial Encephalomyopathy, and Lactic Acidosis and Stroke-like episodes (MELAS).
Original publication
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.